Ebola Virus DiseaseNCT03576690
R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease
A study testing REGN3470-3471-3479 in people with Ebola Virus Disease, run by Regeneron Pharmaceuticals.
Trial summary
Provide access to REGN-EB3 for the treatment of patients with Ebola Virus Disease (EVD). Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Ebola Virus Disease
- What is being tested?
- REGN3470-3471-3479
- How many people
- Not given
- Where
- No sites listed yet
- Study dates
- Start not givento not given
- Phase
- Expanded access
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Who may be able to join
- Males or females in an Ebola endemic region with documented positive polymerase chain reaction (PCR) for Ebola virus infection who are symptomatic
- Ability to provide informed consent personally or by a legal representative if the patient is unable to do so, based on local laws and regulations
- REGN-EB3 can be administered to pregnant women infected with Zaire ebolavirus, as defined in the protocol
- Children of any age will be eligible for enrollment, as defined in the protocol
- Neonates born to an infected mother who has not yet cleared the Ebola virus are eligible for enrollment, as defined in the protocol
Who cannot join
- Negative EBOV diagnostic test result
- A patient who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol
- Any serious medical condition that, in the opinion of the site investigator, would place the patient at an unreasonable increased risk through participation in this study, including any past or concurrent conditions
- Eligible for an ongoing randomized clinical trial with REGN-EB3
- NOTE: Other protocol defined inclusion / exclusion criteria apply
Trial locations and contacts
No sites are listed yet.
Requests for compassionate use must be initiated by a treating physician. Physicians should contact contact
About this study
Official title: Expanded Access Protocol for Emergency Use of REGN3470-3471-3479 for the Treatment of Ebola Virus Disease
Provide access to REGN-EB3 for the treatment of patients with Ebola Virus Disease (EVD).
- Conditions
- Ebola Virus Disease
- Being tested
- REGN3470-3471-3479
- Keywords
- Positive Ebola Virus (EBOV) diagnostic test, symptomatic
- Medical subject headings
- Hemorrhagic Fever, Ebola
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
REGN3470-3471-3479Biological
Also called REGN-EB3, Inmazeb®, atoltivimab, maftivimab, and odesivimab
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jul 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ebola Virus DiseaseStudies of the same condition, open and under way.
- More trials run by Regeneron PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Expanded access
Sponsor and investigators
- Lead sponsor
- Regeneron Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03576690
- Sponsor's protocol ID
- R3470-3471-3479-EBOV-1846
- Status last verified
- Oct 2026
- First submitted
- 22 Jun 2018
- Last updated
- 9 Oct 2026
- Results posted
- No